Holen Sie sich die Stockscreener-App
106.25
1.61%
1.68
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$104.57
Offen:
$106.15
24-Stunden-Volumen:
3.02M
Relative Volume:
0.30
Marktkapitalisierung:
$183.85B
Einnahmen:
$46.59B
Nettoeinkommen (Verlust:
$5.41B
KGV:
34.34
EPS:
3.0938
Netto-Cashflow:
$7.38B
1W Leistung:
+2.46%
1M Leistung:
+7.51%
6M Leistung:
+17.03%
1J Leistung:
-14.78%
1-Tages-Spanne:
$104.60
$106.85
1-Wochen-Bereich:
$101.54
$105.24
52-Wochen-Spanne:
$81.97
$132.03
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
106.25 | 183.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
97.13 | 124.24B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
296.08 | 113.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.08 | 60.98B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.87 | 53.53B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-27 | Herabstufung | Argus | Buy → Hold |
| 2026-10-07 | Eingeleitet | Barclays | Overweight |
| 2026-10-02 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-08-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-07-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott To Spin Off $8.5B Nutrition Business Into Standalone Public Company - https://en.edairynews.com/
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact - The Motley Fool
Abbott Laboratories (ABT) Sees $23.9 Million in Net ETF Buying on Monday - Yahoo Finance
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com
Abbott: Demand Headwinds & Litigation Risks Priced-InSpin-Off Tailwinds Ahead (ABT) - Seeking Alpha
Argus Downgrades Abbott Laboratories to Hold From Buy - marketscreener.com
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Zacks Investment Research
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Yahoo Finance
This Dividend King Just Announced Great News for Investors - The Motley Fool
This Dividend King Just Announced Great News for Investors - The Motley Fool
In Ga. District Court, Product Liability Claim Over Abbott Laboratories' Heart Valve Filed - Law.com
Abbott Laboratories: A New Growth Story Takes Shape (NYSE:ABT) - Seeking Alpha
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool
No change to CG operations as Abbott announces plans to separate nutrition business - PinalCentral.com
What the $8.5B Abbott Nutrition spinoff means for Columbus - The Business Journals
Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device - GlobeNewswire Inc.
Abbott Laboratories announces a baby formula spinoff company - Marketplace.org
Abbott: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Abbott Laboratories plans to spin off nutrition business, following years of tumult over infant formulas - Chicago Tribune
Abbott to Carve Out Nutrition Business Into Independent Company - WSJ
Pre-Markets in Green on Strong Earnings Results - Zacks Investment Research
Pre-Markets Up on Cooling Metrics, Decent Q3 Reports - Zacks Investment Research
Abbott Laboratories to spin off nutrition unit at centre of baby formula lawsuits - Financial Times
Abbott (ABT) Misses Q3 Earnings Estimates - Zacks Investment Research
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
Abbott cuts 2026 sales growth view, plans to spin off nutrition business - Reuters
Abbott Spins Off Embattled Business That Sells Baby Formula - Bloomberg
Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test - Yahoo Finance
Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock - Trefis
Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive? - Yahoo Finance
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
Abbott Q3 preview: What to expect (ABT:NYSE) - Seeking Alpha
The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services - The Globe and Mail
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings - Benzinga
What iShares U.S. Medical Devices ETF (IHI) Sold: Abbott Leads on Friday - Yahoo Finance
Abbott schedules results. Abbott Laboratories stock trades 17.78 percent below its yearly high - ad-hoc-news.de
Key facts: Abbott Laboratories to Report Q3; Cologuard Plus CE Mark - TradingView
Abbott Wins Bid To Move Ex-Worker's Bias Suit To Illinois - Law360
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline - Investing.com
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline By Investing.com - Investing.com India
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Alert incorrectly tagged to Abbott Laboratories withdrawn - marketscreener.com
Abbott Laboratories expected to post earnings of $1.42 a shareEarnings Preview - TradingView
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings - Benzinga
Abbott Laboratories stock at EUR 93.23 ahead of the Xetra open - ad-hoc-news.de
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
Is Abbott Laboratories (ABT) Undervalued Following Product Launches And Growth Expectations? - Simply Wall Street
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle - The Motley Fool
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbott Laboratories-Aktie (ABT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
0.02%
5.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):